Causes Clients Latest News Philanthropically Speaking Recommended Products & Non-Profits

New York Plans to Ban Sale of Big Sizes of Sugary Drinks

New York City plans to enact a far-reaching ban on the sale of large sodas and other sugary drinks at restaurants, movie theaters and street carts, in the most ambitious effort yet by the Bloomberg administration to combat rising obesity.

The proposed ban would affect virtually the entire menu of popular sugary drinks found in delis, fast-food franchises and even sports arenas, from energy drinks to pre-sweetened iced teas. The sale of any cup or bottle of sweetened drink larger than 16 fluid ounces — about the size of a medium coffee, and smaller than a common soda bottle — would be prohibited under the first-in-the-nation plan, which could take effect as soon as next March… New York Plans to Ban Sale of Big Sizes of Sugary Drinks

Causes Clients Latest News Nonprofit Events Philanthropically Speaking

5 Startups Changing the World With Tech

Mashable interviews the faces behind the startups and projects that are working to make a global impact. Blackbaud, Green Spaces, Givey, The Adventure Project and FairShareMusic.

These companies provide technological solutions for non-profits, give fledgling startups a place to work and donate to charity every time a song is downloaded. While the companies are diverse, they are all on a mission to change our lives for the better and improve society…

Causes Entertainment, Arts & Music Events Latest News Nonprofit Events Philanthropically Speaking

Big Picture Soiree Benefiting Chicago Lost & Found for Education in the Community Through the Visual Arts

Big Picture Soiree Benefiting Chicago Lost & Found

Mitchell Pennell and the Board of Chicago Lost and Found invite you to join them May 24, 2012 at 5:30 p.m.  at The Victor, (311 N. Sangamon) for the Big Picture, raising needed support for education in the community through the visual arts.

Featuring spectacular entertainment from cabaret duo Amy Armstrong & Freddy Allenand Chicago’s Cyon Flare!

Buy Your Tickets online for just $40 or at the door.

Enjoy cocktails and tasty treats provided by celebrity Chef Dale LevitskiExecutive Chef of Sprout and the newly opened Frog N Snail.

Thanks to our sponsors!

Pure Kitchen Catering | | The Victor |  Debi Lilly |Andersonville Galleria | Frog N Snail | | |Patrón |

Chicago Lost and Found is a not-for-profit organization dedicated to creative transformation. We are committed to rescuing the discarded and unwanted. Through re-purposing, we create value, which in turn provides creative opportunities to build and support the community.

Causes Entertainment, Arts & Music Events Latest News Nonprofit Events Philanthropically Speaking Recommended Products & Non-Profits

Gala 2012: A Mod Musical Evening Benefits The Music Theatre Company

Last Chance to have fun for a great cause– the performing arts!!!!  Gala 2012: A Mod Musical Evening Benefits The Music Theatre Company  Call for more information or come to the door tonight.

Causes Clients Events Health & Beauty Services Recommended Products & Non-Profits

The Best Home Care Service Around Chicagoland!

The Best Home Care Service Around Chicagoland is Freedom Home Care! Now that I have first hand (literally) experience with Freedom Home Care I can  honestly say in 2 words how I endorse them — simply the best! I have only one hand right now, the other is in a cast for a broken wrist with metal plate & 9 screws.  Thanks to my friends who hired them for me when I was down for the count — their services are invaluable.

Causes Clients Nonprofit Events Philanthropically Speaking

GLASA’s Cindy Housner Talks Inclusion for Disabled Athletes with WGN Radio Host Mike McConnell

Great Lakes Adaptive Sports Association\'s Cindy Housner Talks with WGN Radio Host Mike McConnell on Inclusion of Disabled Athletes in IHSA Events

The Great Lakes Adaptive Sports Association (GLASA) Founder Cindy Housner talks with WGN Radio host Mike McConnell, explaining the arguments for inclusion of athletes with disabiliites in IHSA events. Mike kicks off the hour talking to Cindy about the recent state Attorney General’s order for the IHSA to allow more opportunities for disabled athletes.

Causes Philanthropically Speaking

Promising Alzheimer’s News!

The New York Times By 
Published: May 15, 2012

New Drug Trial Seeks to Stop Alzheimer’s Before It Starts

In a clinical trial that could lead to treatments that preventAlzheimer’s, people who are genetically guaranteed to develop the disease — but who do not yet have any symptoms — will for the first time be given a drug intended to stop it, federal officials announced Tuesday. A version of this article appeared in print on May 16, 2012, on page A1 of the New York edition with the headline: Drug Trial Aims For Prevention of Alzheimer’s.

Experts say the study will be one of the few ever conducted to test prevention treatments for any genetically predestined disease. For Alzheimer’s, the trial is unprecedented, “the first to focus on people who are cognitively normal but at very high risk for Alzheimer’s disease,” said Dr. Francis S. Collins, director of the National Institutes of Health.

Most participants will come from the world’s largest family to experience Alzheimer’s, an extended clan of 5,000 people who live in Medellín, Colombia, and remote mountain villages outside that city. Family members with a specific genetic mutation begin showing cognitive impairment around age 45, and full dementia around age 51, debilitated in their prime working years as their memories fade and the disease quickly assaults their ability to move, eat, speak and communicate.

Three hundred family members will participate in the initial trial. Those with the mutation will be years away from symptoms, some as young as 30.

“Because of this study, we do not feel as alone,” said Gladys Betancur, 39, a family member. Her mother died of Alzheimer’s, three of her siblings already have symptoms, and she had a hysterectomy because of her fears that she has the mutation and would pass it on to her children. “Sometimes we think that life is ending, but now we feel that people are trying to help us.”

The $100 million study will last five years, but sophisticated tests may indicate in two years whether the drug helps delay memory decline or brain changes, said Dr. Eric M. Reiman, executive director of the Banner Alzheimer’s Institute in Phoenix and a study leader.

Alzheimer’s experts not involved in the study said that though only a small percentage of people with Alzheimer’s have the genetic early-onset form that affects the Colombian family, the trial was expected to yield information that could apply to millions of people worldwide who will develop more conventional Alzheimer’s.

“It offers a tremendous opportunity for us to answer a large number of questions, while at the same time offering these people some significant clinical help that otherwise they never would have had,” said Dr. Steven T. DeKosky, an Alzheimer’s researcher who is vice president and dean of the University of Virginia School of Medicine. Dr. DeKosky was part of a large group consulted early on, but is not involved in the study.

Some 5.4 million Americans have Alzheimer’s, and the numbers are expected to swell as the baby boom generation ages. Dr. Reiman’s team is planning a similar trial for people in the United States considered at increased risk for conventional late-onset Alzheimer’s. The study announced Tuesday will include a small number of Americans with gene mutations guaranteed to cause early-onset Alzheimer’s.

The drug trial is part of the federal government’s first national plan to address Alzheimer’s, which was unveiled Tuesday by Kathleen Sebelius, the secretary for health and human services. The government took the unusual step of assigning $50 million from the current year’s N.I.H. budget to research considered too promising to wait, including the Colombia trial and a study on whether inhaled insulin can ease mild cognitive impairment, Dr. Collins said. Another $100 million is proposed for 2013, mostly for research, but also for education, caregiver support and data collection.

Success for the Colombia trial is, of course, no sure thing. Many trials fail, and Alzheimer’s research has so far found no treatment effective for more than several months. But experts say that trying drugs years before symptoms emerge could have greater potential because the brain would not yet be ravaged by the disease. The trial will be financed with $16 million from the National Institutes of Health, $15 million from private donors through the Banner Institute and about $65 million from Genentech, the drug’s American manufacturer.

The drug, Crenezumab, attacks amyloid plaques in the brain. If it can forestall memory or cognitive problems, scientists will know that prevention or delay is possible and appears to lie in targeting amyloid years before dementia develops. Many, but not all, Alzheimer’s researchers believe amyloid is an underlying cause of Alzheimer’s.

In 2010, The New York Times reported on the pervasiveness of dementia in this large Colombian family and scientists’ hopes of testing prevention drugs. But persuading pharmaceutical companies to invest took months. There are scientific and ethical issues involved with giving drugs to people who are healthy and people who live in a developing country, some of whom have little education, paltry incomes and longstanding superstitions about the disease they call La Bobera — the foolishness.

“The first thing I did was to ask myself the question, Are we taking advantage of these folks?” said Richard H. Scheller, Genentech’s executive vice president of research and early development. “The answer was clearly no.”

The risks, he said, are balanced by the fact that if nothing is done, “they’re going to get this terrible, terrible disease for sure.”

The few trials of prevention therapies — involving ginkgo biloba, women’s hormone replacement treatment and anti-inflammatory drugs — have involved people not guaranteed to get the disease. These therapies either failed or caused adverse side effects.

Testing drugs on that kind of population takes “too many healthy volunteers, too much money, and too many years,” Dr. Reiman said.

The Colombian population is ideal because it is large enough to provide solid results, and it is easy to identify whom the disease will strike and when.

Crenezumab was chosen for the Colombia trial partly because it appears to have no negative side effects, unlike other drugs designed to clear amyloid from the brain, said Dr. Francisco Lopera, a Colombian neurologist who has worked with the family for decades and is a leader of the study. Other anti-amyloid treatments have caused edema in the blood vessels, an imbalance of fluid that can have serious consequences.

Crenezumab is currently being given in two clinical trials to people with mild to moderate symptoms of dementia in the United States, Canada and Western Europe to see if it can help reduce cognitive decline or amyloid accumulation, according to Genentech.

In the Colombia study, expected to start early next year, 100 family members with the mutation will receive the drug every two weeks in an injection at a hospital. Another 100 carriers will receive a placebo. And because many people do not want to know if they have the mutation, researchers will include 100 noncarriers in the study; they will receive a placebo.

Researchers have developed a sophisticated battery of five memory and cognitive tests that have been shown in other studies to detect subtle alterations in recall and thinking ability that usually go unnoticed. Dr. Pierre N. Tariot, director of the Banner Institute and a leader of the study, said the measurements would involve recalling words, naming objects, nonverbal reasoning, remembering time and place, and drawing tests involving copying complex figures.

Dr. Tariot said researchers would also assess changes in people’s emotional state, “irritability, sadness, crying, anxiety, impulsivity — these are cardinal features of the disease as it emerges.”

The scientists will take physiological measurements, including PET scans that measure amyloid and how glucose is metabolized in the brain, M.R.I. scans that measure whether the brain is shrinking, and cerebral spinal fluid tests that measure amyloid and tau, a protein in dying brain cells.

If any of these indicators are improved by the drug, Dr. Reiman said, scientists may then be able to treat one of these early physiological changes, just as high blood pressure and cholesterol are treated to prevent heart disease.

In Medellín, Marcela Agudelo, 17, has Alzheimer’s on both sides of her family because her parents are distant cousins. Marcela watched her maternal grandmother die, and her father, 55, once a vibrant livestock trader, has deteriorated so much that he can no longer walk, talk or laugh.

With the research, “we have more hope for a cure,” Marcela said, “or at least a better life.”

Dabrali Jimenez contributed reporting.

Todd Heisler/The New York Times Brain scans of a member of a Colombian family who has Alzheimer’s, which leads to dementia.

Causes Events Latest News Nonprofit Events Philanthropically Speaking

The Be-Well Lake County Community Dig Day

This diabetes education, treatment and awareness program is a community health initiative at its best, Committed to providing greater access to comprehensive diabetes care and education for medically underserved patients in Lake County, the Auxiliary at NorthShore Highland Park Hospital, through its annual appeal, has donated nearly $700,000 to this initiative. To donate, contact The Auxiliary at And, consider joining us on dig day

Causes Events Nonprofit Events Philanthropically Speaking

Pre-Mother’s Day Sale in Progress at Alcove Gifts at NorthShore Highland Park Hospital

Only 3 more days to shop at the Alcove Gift Shop for Mother’s Day while supporting your local hospital. A fundraising arm of the Auxiliary at NorthShore Highland Park Hospital, the Alcove’s proceeds benefit health programs at the Hospital. Fabulous merchandise! Stop in & shop. Highland Park Hospital. 777 Park Ave, HP. Complimentary valet parking

Causes Entertainment, Arts & Music Events Latest News Nonprofit Events Philanthropically Speaking

Chicago’s Mars Gallery Opening Night of Montezuma Nights-Bradley Weiss’ Photo Exhibition Benefiting Rush University Medical Center For Parkinson’s Disease

Opening night reception of Bradley S. Weiss’ photo exhibition at Chicago’s Mars Gallery benefiting Rush University Medical Center to thank and honor their Movement Disorder Group & Neurosurgical Teams for treating Brad’s Parkinson’s Disease and giving him his life back!

Music by The Sidecars, a jazzy sound with a south American edge. Catering by Highland Park’s hottest new bistros, 2nd Street Bistro & Enoteca
Libations donated by Brad’s old law fim of Miner Barnhill & Galland

Curated by Susan Aurinko
Featuring Photography of Bradley s, Weiss and Leah Weiss